Known targets — ChEMBL curated mechanism
COXFA4COXFA4L2GPD2MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3
The experimentally established mechanism targets of Metformin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 1/20 | 0.38 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | NOS3 | P29474 | 1/20 | 0.30 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Metformin SCHEMBL2815239 | 0.98 | LDHA (0.36) | LDHASRRCYP2C19 | |
| Metformin SCHEMBL991100 | 0.90 | FFAR3 (0.40) | CYP2C19 | |
| Metformin SCHEMBL7647374 | 0.90 | PHF8 (0.41) | CYP2C19 | |
| Metformin SCHEMBL1557197 | 0.90 | GLRA1 (0.40) | CYP2C19 | |
| Metformin SCHEMBL1558869 | 0.90 | PHF8 (0.41) | CYP2C19 | |
| Metformin SCHEMBL7123890 | 0.88 | PHF8 (0.39) | — | |
| Metformin SCHEMBL4364474 | 0.87 | LMNA (0.30) | — | |
| Metformin SCHEMBL1323029 | 0.87 | CRBN (0.33) | — | |
| Metformin SCHEMBL4410446 | 0.87 | CRBN (0.33) | — | |
| Adipic Acid SCHEMBL2812145 | 0.86 | LMNA (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2519240-B1 | PHARMACEUTICAL COMPOSITION COMPRISING METFORMIN AND ROSUVASTATIN | BCWORLD PHARM CO LTD (KR) | 2018-02-07 | — | — | EP | claimed |
| US-9005636-B2 | Pharmaceutical composition comprising metformin and rosuvastatin | BCWORLD PHARM CO., LTD. (KR) | 2015-04-14 | — | — | US | claimed |
| CN-101855204-B | N,N-dimethyl imidodicarbonimidic diamide dicarboxylate, method for producing the same and pharmaceutical compositions comprising the same | HANALL BIOPHARMA CO LTD | 2013-09-11 | — | — | CN | claimed |
| US-20130035316-A1 | PHARMACEUTICAL COMPOSITION COMPRISING METFORMIN AND ROSUVASTATIN | BCWORLD PHARM. CO., LTD. (KR) | 2013-02-07 | — | — | US | claimed |
| EP-2519240-A2 | PHARMACEUTICAL COMPOSITION COMPRISING METFORMIN AND ROSUVASTATIN | Bcworld Pharm. Co. Ltd. (KR) | 2012-11-07 | — | — | EP | claimed |
| CN-102762209-A | Pharmaceutical composition comprising metformin and rosuvastatin | BCWORLD PHARM CO LTD | 2012-10-31 | — | — | CN | claimed |
| WO-2011081493-A2 | PHARMACEUTICAL COMPOSITION COMPRISING METFORMIN AND ROSUVASTATIN | BCWORLD PHARM. CO., LTD. (KR) | 2011-07-07 | — | — | WO | claimed |
| CN-115006378-A | Medicine for preventing or treating metabolic diseases or metabolic dysfunction diseases | 西安莱格瑞生物科技有限公司 | 2022-09-06 | — | — | CN | disclosed |
| EP-2519240-B1 | PHARMACEUTICAL COMPOSITION COMPRISING METFORMIN AND ROSUVASTATIN | BCWORLD PHARM CO LTD (KR) | 2018-02-07 | — | — | EP | disclosed |
| EP-2203418-B1 | N,N-DIMETHYL IMIDODICARBONIMIDIC DIAMIDE DICARBOXYLATE, METHOD FOR PRODUCING THE SAME AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | HANALL BIOPHARMA CO LTD (KR) | 2017-10-25 | — | — | EP | disclosed |
| US-9700531-B2 | Composition comprising metformin as active ingredient for preventing or treating inflammatory bowel disease | Catholic University Industry Academic Cooperation Foundation (KR) | 2017-07-11 | — | — | US | disclosed |
| US-20170157069-A1 | COMPOSITION USING METFORMIN FOR PREVENTING OR TREATING IMMUNE DISEASES INCLUDING LUPUS | Catholic University Industry Academic Cooperation Foundation (KR) | 2017-06-08 | — | — | US | disclosed |
| US-20150238445-A1 | COMPOSITION USING METFORMIN FOR PREVENTING OR TREATING IMMUNE DISEASES INCLUDING LUPUS | Catholic University Industry Academic Cooperation Foundation (KR) | 2015-08-27 | — | — | US | disclosed |
| CN-102762209-A | Pharmaceutical composition comprising metformin and rosuvastatin | BCWORLD PHARM CO LTD | 2012-10-31 | — | — | CN | disclosed |
| US-8076377-B2 | N,N-dimethyl imidodicarbonimidic diamide dicarboxylate, method for producing the same and pharmaceutical compositions comprising the same | HANALL PHARMACEUTICAL COMPANY, LTD. (KR) | 2011-12-13 | — | — | US | disclosed |
| WO-2011081493-A2 | PHARMACEUTICAL COMPOSITION COMPRISING METFORMIN AND ROSUVASTATIN | BCWORLD PHARM. CO., LTD. (KR) | 2011-07-07 | — | — | WO | disclosed |
| CN-101855204-A | N,N-dimethyl imidodicarbonimidic diamide dicarboxylate, method for producing the same and pharmaceutical compositions comprising the same | HANALL PHARMACEUTICAL COMPANY LTD | 2010-10-06 | — | — | CN | disclosed |
| US-20100249241-A1 | N,N-DIMETHYL IMIDODICARBONIMIDIC DIAMIDE DICARBOXYLATE, METHOD FOR PRODUCING THE SAME AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | HANALL PHARMACEUTICAL COMPANY, LTD. (KR) | 2010-09-30 | — | — | US | disclosed |
| EP-2203418-A2 | N,N-DIMETHYL IMIDODICARBONIMIDIC DIAMIDE DICARBOXYLATE, METHOD FOR PRODUCING THE SAME AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | Hanall Pharmaceutical Company LTD. (KR) | 2010-07-07 | — | — | EP | disclosed |
| WO-2009038396-A2 | N,N-DIMETHYL IMIDODICARBONIMIDIC DIAMIDE DICARBOXYLATE, METHOD FOR PRODUCING THE SAME AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | HANALL PHARMACEUTICAL COMPANY. LTD (KR) | 2009-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249241-A1 | N,N-DIMETHYL IMIDODICARBONIMIDIC DIAMIDE DICARBOXYLATE, METHOD FOR PRODUCING THE SAME AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | TNNC1, TP53, CAD | LDHA 293/4885SRR 3453/4885CYP2C19 2879/4885 |
| US-20170157069-A1 | COMPOSITION USING METFORMIN FOR PREVENTING OR TREATING IMMUNE DISEASES INCLUDING LUPUS | SSB, NFATC1, IL17A | LDHA 3836/4885SRR 3366/4885CYP2C19 1184/4885 |
| US-20150238445-A1 | COMPOSITION USING METFORMIN FOR PREVENTING OR TREATING IMMUNE DISEASES INCLUDING LUPUS | SSB, NFATC1, IL17A | LDHA 3836/4885SRR 3366/4885CYP2C19 1184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.